Constantine George, MD
Internal Medicine · Las Vegas, NVNPI 1164429858
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 70 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $465, 3.2 times the $148 reported in 2019.
Across 70 payments — averaging $17.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Antares Pharma, Inc.$205
- AbbVie$166
- Gilead$80
- Novo Nordisk$68
- Abbott$65
- Aytu Biopharma, Inc.$50
- plus $573 from 24 others
What the payments were for
- Food & beverage$1,19499%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Antares Pharma, Inc. | 18 | $205 |
| AbbVie | 8 | $166 |
| Gilead | 4 | $80 |
| Novo Nordisk | 3 | $68 |
| Abbott | 3 | $65 |
| Aytu Biopharma, Inc. | 3 | $50 |
| Novartis | 2 | $43 |
| Pfizer | 2 | $41 |
| AstraZeneca | 2 | $38 |
| IBSA Pharma Inc. | 2 | $36 |
| Cranial Technologies, Inc | 2 | $35 |
| Viiv Healthcare Company | 1 | $34 |
| Boston Scientific | 2 | $29 |
| Lilly USA, LLC | 2 | $26 |
| UCB, Inc. | 1 | $25 |
| Optinose US, Inc. | 1 | $25 |
| Amgen | 1 | $24 |
| Impel Pharmaceuticals Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $19 |
| Exact Sciences | 1 | $19 |
| Dexcom, Inc. | 1 | $19 |
| Bayer | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Merck | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Upsher-smith Laboratories LLC | 1 | $14 |
| Tolmar, Inc. | 1 | $14 |
How this compares
$1,205 in reported general payments places this provider in the 75th percentile of 1,071 internal medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 26 | $28,151 |
| OzempicSemaglutide | 20 | $27,472 |
| JanuviaSitagliptin Phosphate | 20 | $26,413 |
| TrulicityDulaglutide | 21 | $26,332 |
| MounjaroTirzepatide | 18 | $24,271 |
| XareltoRivaroxaban | 13 | $12,476 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $7,082 |
| SynthroidLevothyroxine Sodium | 49 | $4,837 |
| Rosuvastatin Calcium | 59 | $1,087 |
| Levothyroxine Sodium | 127 | $952 |
| Amlodipine Besylate | 146 | $865 |
| Atorvastatin Calcium | 158 | $856 |
| Gabapentin | 37 | $683 |
| Pantoprazole Sodium | 54 | $654 |
| Montelukast Sodium | 95 | $613 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $26 | $50,60339 claims |
| MerckJanuvia, Janumet | $17 | $33,49532 claims |
| PfizerEliquis | $41 | $28,15126 claims |
| Novo NordiskOzempic | $68 | $27,47220 claims |
| Johnson & JohnsonXarelto | $19 | $12,47613 claims |
| AbbVieSynthroid | $166 | $4,83749 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,071 internal medicine providers in Nevada.
Other internal medicine in Las Vegas
- Kevin DunsmoorLas Vegas$241K
- Robert ChiascioneLas Vegas$174K
- Dino GonzalezLas Vegas$126K
- Rosanne SugayLas Vegas$63K
- Chad HallLas Vegas$42K
- Zubin DamaniaLas Vegas$40K
- Audrey Sue CruzLas Vegas$34K
- Bashab BanerjiLas Vegas$26K
- Amaan ShafiLas Vegas$25K
- Sassan KavehLas Vegas$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.